<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624401</url>
  </required_header>
  <id_info>
    <org_study_id>LOC-2016</org_study_id>
    <nct_id>NCT02624401</nct_id>
  </id_info>
  <brief_title>The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)</brief_title>
  <official_title>The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and
      electroencephalography (EEG) studies will be carried out to reveal the neural correlates of
      consciousness. Consciousness of the subjects will be manipulated with anesthetic agents
      dexmedetomidine, propofol, S-ketamine and sevoflurane. One-hundred-and-sixty (160) healthy
      male subjects will be recruited to receive EC50 concentration of the anesthetic (40
      dexmedetomidine, 40 propofol, 20 S-ketamine, 40 sevoflurane) or placebo (20) while being
      imaged for cerebral metabolic rate of glucose (CMRglu). Also genetic, immunological and
      metabolomics samples will be taken and analysed to find possible genetic factors explaining
      the variability in drug response and to find chemical fingerprints of acute drug effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The explanation of consciousness poses one of the greatest challenges to science and
      philosophy in the 21st century. It remains unclear what consciousness is and how it emerges
      from brain activity. Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and
      electroencephalography (EEG) studies will be carried out to reveal the neural correlates of
      consciousness. Consciousness of the subjects will be manipulated with anesthetic agents
      dexmedetomidine acting through α2-agonism, with propofol and sevoflurane both mainly acting
      through the enhancement of gamma-aminobutyric acid (GABA) system, and with S-ketamine acting
      through N-methyl-D-aspartate (NMDA) receptor antagonism. One-hundred-and-sixty (160) healthy
      male subjects will be recruited to receive EC50 concentration of either dexmedetomidine,
      propofol, S-ketamine or sevoflurane, or placebo while being imaged for cerebral metabolic
      rate of glucose (CMRglu). 40 subjects will receive dexmedetomidine, 40 subjects propofol, 20
      subjects S-ketamine, 40 subjects sevoflurane and 20 subjects will receive placebo. Also
      genetic, immunological and metabolomics samples will be taken and analysed to find possible
      genetic factors explaining the variability in drug response and to find possible
      immunological and chemical fingerprints of acute drug effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional cerebral metabolism of glucose</measure>
    <time_frame>40 min</time_frame>
    <description>Comparison of responsive and unresponsive subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG</measure>
    <time_frame>1 hour</time_frame>
    <description>64-channel EEG will be recorded and analyzed using time domain, spectral domain, functional connectivity, directed/effective connectivity and graph theoretical analysis methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological effects</measure>
    <time_frame>2 hours</time_frame>
    <description>Blood samples will be draw at baseline (without drug), at the end of study drug administration and after PET scanning for the measurement of approximately 50 cytokines, chemokines and growth factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic effects</measure>
    <time_frame>2 hours</time_frame>
    <description>Blood samples will be drawn at baseline (without drug), at the end of drug administration and after PET scanning for the measurement of more than 200 serum measures, including lipoprotein subclass distribution and lipoprotein particle concentration, low molecular weight metabolites, such as amino acids, 3-hydroxybutyrate and creatinine, and detailed molecular information on serum lipids, including free and esterified cholesterol, sphingomyelin and fatty acid saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression</measure>
    <time_frame>2 hours</time_frame>
    <description>Blood samples will be collected at baseline (without drug), at the end of drug administration and after PET scanning for the measurement of RNA expression using whole genome microarray-based, massively parallel sequencing or quantitative reverse-transcription polymerase chain reaction based methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological well-being</measure>
    <time_frame>2 hours</time_frame>
    <description>Psychological well-being and ill-being will be measured with a battery of scientifically validated scales just before initiating the study session and at the end of the study session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dream report</measure>
    <time_frame>1 hour</time_frame>
    <description>After terminating PET imaging, a structured interview is immediately conducted to verify a recollection or absence of recollection of subjective experiences during possible loss of responsiveness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug concentration in plasma or end-tidal</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Anesthesia</condition>
  <condition>Unconsciousness</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous dexmedetomidine using target controlled infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous propofol using target controlled infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous S-ketamine using target controlled infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalational sevoflurane using target controlled inhalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol-Lipuro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-ketamine</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>S-ketamine</arm_group_label>
    <other_name>Ketanest-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of saline (Ringer's Acetate)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male

          2. Age 18-30 years

          3. Good general health i.e. American Society of Anesthesiologists (ASA) physical status I

          4. Fluent in Finnish language

          5. Right handedness

          6. Written informed consent

          7. Good sleep quality

        Exclusion Criteria:

          1. Chronic medication

          2. History of alcohol and/or drug abuse

          3. Strong susceptibility for allergic reactions

          4. Serious nausea in connection with previous anesthesia

          5. Strong susceptibility for nausea

          6. Any use of drugs or alcohol during the 48 hours preceding anesthesia

          7. Use of caffeine products 10-12 hours prior the study

          8. Smoking

          9. Clinically significant previous cardiac arrhythmia / cardiac conduction impairment

         10. Clinically significant abnormality in prestudy laboratory tests

         11. Positive result in the drug screening test

         12. Blood donation within 90 days prior to the study

         13. Participation in any medical study with an experimental drug or device during the
             preceding 60 days

         14. The study subject has undergone a prior PET or SPECT study

         15. Any contraindication to magnetic resonance imaging (MRI)

         16. Hearing impairment

         17. Detected unsuitability based on MRI scanning results if available before the PET
             scanning

         18. Sleep disorder or severe sleep problem
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>FI-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.aka.fi/globalassets/32akatemiaohjelmat/mind/hankekuvaukset/mieli-revonsuo.pdf</url>
    <description>Academy of Finland: The MIND program</description>
  </link>
  <reference>
    <citation>Långsjö JW, Alkire MT, Kaskinoro K, Hayama H, Maksimow A, Kaisti KK, Aalto S, Aantaa R, Jääskeläinen SK, Revonsuo A, Scheinin H. Returning from oblivion: imaging the neural core of consciousness. J Neurosci. 2012 Apr 4;32(14):4935-43. doi: 10.1523/JNEUROSCI.4962-11.2012.</citation>
    <PMID>22492049</PMID>
  </reference>
  <reference>
    <citation>Långsjo JW, Revonsuo A, Scheinin H. Harnessing anesthesia and brain imaging for the study of human consciousness. Curr Pharm Des. 2014;20(26):4211-24. Review.</citation>
    <PMID>24025060</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Harry Scheinin</investigator_full_name>
    <investigator_title>Adjunct Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

